Clinical approach identifies behavioral and plasma markers for diagnosing and predicting outcomes in Parkinson’s disease, highlighting the significance of immune signatures.
Key Points
This research aims to differentiate Parkinson’s disease from Stiff-person syndrome using behavioral and plasma biomarkers, while examining prognostic factors.
Prospective enrollment of 133 Parkinson’s disease participants from a medical college.
Standardized evaluations using UPDRS and PD-CFRS at baseline and follow-ups.
Quantification of plasma biomarkers including Clusterin and anti-CCP antibody via enzyme-linked immunosorbent assay.
Correlation and hierarchical regression analyses to examine relationships and prognostic trajectories.
Significant declines in clinical domains across follow-ups (P < 0.001 for UPDRS scores).
Plasma Clusterin concentrations decreased from 125.68 to 115.16 µg/mL (P < 0.001).
Anti-CCP antibody levels declined significantly; anti-GAD antibody levels remained unchanged.
Moderate positive correlation found between anti-CCP concentrations and UPDRS-CF scores (r = 0.30).